tiprankstipranks
Spero Therapeutics (NASDAQ:SPRO) Soars on Major GSK Deal
Market News

Spero Therapeutics (NASDAQ:SPRO) Soars on Major GSK Deal

Spero Therapeutics (NASDAQ:SPRO) is flying high in the pre-market session today after a multitude of positive developments. The company has entered into an exclusive license agreement with GSK for the former’s antibiotic candidate, tebipenem HBr.

The late-stage product is targeted for the treatment of complicated urinary tract infections. The agreement helps GSK boost its pipeline of late-stage products.

Importantly, the Phase 3 trial of the drug is expected to begin in 2023. The deal includes an upfront payment of $66 million, total milestone payments of $525 million, and royalties in low-single digit to low double-digit for Spero.

But there’s more, GSK is also making a $9 million investment in Spero. The market capitalization of the company currently stands at ~$31 million!

The transactions are anticipated to close in Q4 2022.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles